Cibus Sees Annual Biofragrance Revenue of About $100 Million
Key Facts
In its business update issued on November 12, Cibus said its biofragrance business could generate peak annual revenue of nearly $100 million once fully commercialized, assuming a portfolio of eight ingredients. The figure is tied to the direct-sales model the company currently follows, rather than the royalty model underlying earlier estimates. The partner confirmed its approval to use the first two biofragrance ingredients in its products. Cibus has begun manufacturing in preparation for expected production batches. The update places the revenue estimate alongside ongoing execution steps, while achieving the stated level remains conditional on full commercialization and the assumed portfolio.
The partnership extends to additional ingredients: the partner requested larger quantities of two other fragrances to support product development, while continuing to evaluate other fragrance ingredients. The company said its initial fragrances are produced using its proprietary yeast and then extracted after fermentation. This commercial approach differs from collecting royalties on sales, as the announced revenue estimate reflects Cibus operating under a direct-sales model. The partner's approval of the first two ingredients signals their move into use in products, while the additional ingredients remain tied to product development and evaluation. The company did not specify in the update when full commercialization of the fragrance portfolio would be completed.
In its rice program, Cibus said herbicide-tolerance traits performed well in field trials in Latin America during 2026. Trials of test varieties were planted in April, and results came in August. In a subsequent step, customer Interoc planted the traits in its own varieties in Ecuador in late September, and the company expects results in the first quarter of 2027. Cibus continues to work toward a definitive commercialization agreement with Interoc, which would give the company the right to sell seeds carrying its traits in Interoc's markets in exchange for royalties on planted acreage. The company says the initial commercial launch of rice in Latin America could come as early as 2028, if the agreement and commercial path move forward.
Cibus estimated the annual royalty opportunity from its portfolio of rice traits at about $200 million, based on a maximum addressable area of between 5 and 7 million acres. This remains a company estimate tied to reaching the projected acreage, not revenue recognized in quarterly results. In terms of current financial performance, revenue for the third quarter ended September 30, 2026, was about $800,000, compared with $615,000 in the corresponding period of 2025. These results provide a picture of activity recorded during the quarter, while the biofragrance and rice estimates are based on future commercial opportunities and commercialization stages that have not yet been completed. The update did not provide a figure for biofragrance sales achieved during the quarter.
Cash and cash equivalents totaled $10.7 million on September 30, 2026, and Cibus said this was sufficient to fund planned operating and capital expenditures through early in the first quarter of 2027. The company used $30.2 million in cash for operating activities during the first nine months of 2026, down about 19% from $37.2 million in the corresponding period of the previous year. Even so, the company expects its annual cash burn to reach about $35 million by the end of 2026. The stated funding runway makes the pace of execution across the biofragrance and rice programs a factor linked to available liquidity, according to the company's estimates for the coming period. The update did not announce an extension of the expense coverage period beyond early in the first quarter of 2027.
CBUS shares closed at $1.09 in the November 12 session, down 6.47%, after trading between $1.07 and $1.22. The session close came before the results were announced after the market closed, according to Reuters via Investing.com. Reuters reported that the stock closed down 6.03% from the previous session's close of $1.16, and said it was unchanged in after-hours trading. The comparison between the two sources shows a difference in the reported session decline, while both agree on the $1.09 closing price. The stock's move came on the day the company updated its programs and results, while the next announced operating milestones extend to the expected Ecuador trial results in the first quarter of 2027, followed by the potential initial rice launch in 2028.